Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice
Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our...
Saved in:
Published in | Breast cancer research : BCR Vol. 11; no. 5; p. R72 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
01.01.2009
National Library of Medicine - MEDLINE Abstracts BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics.
We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography.
The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice.
These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. |
---|---|
AbstractList | Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. Methods We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGF[beta]1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. Results The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGF[beta]1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. Conclusions These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGF[beta]1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. INTRODUCTION: Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. METHODS: We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFβ1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. RESULTS: The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFβ1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. CONCLUSIONS: These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFβ1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. INTRODUCTIONExpression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. METHODSWe subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. RESULTSThe hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. CONCLUSIONSThese data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGF[beta]1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGF[beta]1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGF[beta]1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. Methods We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFI21) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. Results The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFI21 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. Conclusions These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFI21 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. Abstract Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. Methods We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFβ1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. Results The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFβ1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. Conclusions These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFβ1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype. |
ArticleNumber | R72 |
Audience | Academic |
Author | Barcellos-Hoff, Mary Helen Bissell, Mina J Shyamala, Gopalan Simian, Marina |
AuthorAffiliation | 1 Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA 2 Current address: Research Area, Instituto de Oncología 'Ángel H. Roffo', Avda San Martín 5481, Buenos Aires C1417DTB, Argentina 3 Current address: Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue, New York, NY 10016, USA |
AuthorAffiliation_xml | – name: 1 Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA – name: 3 Current address: Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue, New York, NY 10016, USA – name: 2 Current address: Research Area, Instituto de Oncología 'Ángel H. Roffo', Avda San Martín 5481, Buenos Aires C1417DTB, Argentina |
Author_xml | – sequence: 1 givenname: Marina surname: Simian fullname: Simian, Marina email: marina.simian@galuzzi.com organization: Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA. marina.simian@galuzzi.com – sequence: 2 givenname: Mina J surname: Bissell fullname: Bissell, Mina J – sequence: 3 givenname: Mary Helen surname: Barcellos-Hoff fullname: Barcellos-Hoff, Mary Helen – sequence: 4 givenname: Gopalan surname: Shyamala fullname: Shyamala, Gopalan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19788752$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kkuLFDEQxxtZcR-K30CCgnuaNUl3Hu1BGJZ1FRYUUfAW0unq6SzdSZv0LOzVT26NM-iMqOSQoupX_6Qep8VRiAGK4imjF4xp-apxiVdUPyhOWCXFQlT869GefVyc5nxLKVNa6EfFMauV1krwk-L7VZ5TXEEgNrRk2ph5hoTqJIGDaY4pk97eAWl9nn1wM0lxgEx8IHMPBGnbDD73I4SZxO6ns7-fIE2DxQRHph5CnNGzSfn4abEkc7Ih45MYHL2Dx8XDzg4Znuzus-LL26vPl-8WNx-u318ubxaNLOW8EIK5su1YrSV0jRTS1W1jS1XSTslKaNnoRrSqog5apZjtnGsVt1yAa6ksWXlWvNnqTutmhNbhh5MdzJT8aNO9idabw0jwvVnFO8NVTbXgKPB6K9D4-A-Bw4iLo9lNBpPPd6-n-G2NbTOjzw6GwQaI62xUWbGaK10j-fK_JMex6lpWCD7_A7yN6xSwh4aXknFR6RKhF1toZQcwPnQRv-Y2imbJGeVVLWqK1MVfKDwt4IhwGzqP_oOEXTkuxZwTdL_awKjZrORe4c_22_6b2-1g-QM0weGF |
CitedBy_id | crossref_primary_10_1016_j_etap_2021_103785 crossref_primary_10_1016_j_mce_2015_09_023 crossref_primary_10_3390_cells9092074 crossref_primary_10_1530_ERC_11_0378 crossref_primary_10_3389_fcell_2020_00415 crossref_primary_10_1186_s12885_018_4550_z crossref_primary_10_3109_10253890_2011_624223 crossref_primary_10_1016_j_jmb_2016_06_020 crossref_primary_10_1042_EBC20200163 crossref_primary_10_1158_0008_5472_CAN_13_0021 crossref_primary_10_1016_j_jsbmb_2024_106515 |
Cites_doi | 10.1016/0092-8674(95)90199-X 10.1006/mgme.1999.2897 10.1083/jcb.125.3.681 10.1083/jcb.200302090 10.1242/dev.112.2.439 10.1083/jcb.118.5.1271 10.1016/S1071-5576(99)00058-1 10.1146/annurev.bi.63.070194.002315 10.1023/A:1014820500738 10.1101/gad.9.18.2266 10.1016/S0092-8674(03)00432-X 10.1186/bcr65 10.1016/S0002-9440(10)61158-3 10.1177/153537020222701104 10.1083/jcb.148.3.615 10.1023/A:1026339111278 10.1016/0012-1606(83)90086-6 10.1016/S0002-9440(10)62985-9 10.1016/j.tcb.2008.08.007 10.1126/science.1131000 10.1016/S0960-0760(01)00182-0 10.1073/pnas.95.2.696 10.1093/carcin/24.3.403 10.1091/mbc.6.10.1287 10.1016/S0960-0760(97)00128-3 10.1073/pnas.97.7.3044 10.1136/jcp.54.8.624 10.1186/bcr634 10.1016/S0002-9440(10)65589-7 10.1016/S0092-8674(00)81009-0 10.1128/MCB.15.4.1847 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2009 BioMed Central Ltd. Copyright National Library of Medicine - MEDLINE Abstracts 2009 Copyright ©2009 Simian et al.; licensee BioMed Central Ltd. 2009 Simian et al.; licensee BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2009 BioMed Central Ltd. – notice: Copyright National Library of Medicine - MEDLINE Abstracts 2009 – notice: Copyright ©2009 Simian et al.; licensee BioMed Central Ltd. 2009 Simian et al.; licensee BioMed Central Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7QO 8FD FR3 P64 7X8 5PM |
DOI | 10.1186/bcr2408 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic Engineering Research Database CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1465-542X |
EndPage | R72 |
ExternalDocumentID | oai_biomedcentral_com_bcr2408 1933472201 A210249590 10_1186_bcr2408 19788752 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | United States Argentina |
GeographicLocations_xml | – name: Argentina – name: United States |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: U54CA112970 – fundername: NCI NIH HHS grantid: U54CA126552 – fundername: NCI NIH HHS grantid: R01 CA129523 – fundername: NCI NIH HHS grantid: R01CA057621 – fundername: NCI NIH HHS grantid: R01 CA057621-10 – fundername: NCI NIH HHS grantid: R01 CA057621 – fundername: NCI NIH HHS grantid: 5 R01CA064786 – fundername: NIA NIH HHS grantid: R01 AG022413 |
GroupedDBID | --- 04C 0R~ 23N 2VQ 2WC 3V. 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACJQM ACMJI ACPRK ACRMQ ADBBV ADFRT ADINQ ADUKV AENEX AFKRA AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BMSDO BPHCQ BVXVI C1A C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EIHBH EJD F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO ICW IHR INH INR ITC KQ8 LGEZI LOTEE NADUK NPM NXXTH O5R O5S O9- OK1 P2P PGMZT PIMPY PQQKQ PROAC RBZ ROL RPM RSV SBL SOJ TR2 U2A UKHRP WOQ AAYXX CITATION AFPKN K9. 7QO 8FD FR3 P64 7X8 ABVAZ AFGXO AFNRJ ZA5 5PM |
ID | FETCH-LOGICAL-b636t-551c3df1986efb656c9dba3730f764586b8b5d740ced771afccd72a25ecd06313 |
IEDL.DBID | RBZ |
ISSN | 1465-542X 1465-5411 |
IngestDate | Tue Sep 17 21:28:34 EDT 2024 Wed May 22 07:10:52 EDT 2024 Fri Oct 25 03:07:22 EDT 2024 Fri Oct 25 07:50:31 EDT 2024 Thu Oct 10 17:34:41 EDT 2024 Wed Jul 24 18:22:29 EDT 2024 Tue Nov 12 23:37:02 EST 2024 Wed Oct 09 16:48:59 EDT 2024 Tue Oct 15 23:41:40 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b636t-551c3df1986efb656c9dba3730f764586b8b5d740ced771afccd72a25ecd06313 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://dx.doi.org/10.1186/bcr2408 |
PMID | 19788752 |
PQID | 236125483 |
PQPubID | 42565 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2790852 biomedcentral_primary_oai_biomedcentral_com_bcr2408 proquest_miscellaneous_734192789 proquest_miscellaneous_21468964 proquest_journals_236125483 gale_infotracmisc_A210249590 gale_infotracacademiconefile_A210249590 crossref_primary_10_1186_bcr2408 pubmed_primary_19788752 |
PublicationCentury | 2000 |
PublicationDate | 2009-01-01 |
PublicationDateYYYYMMDD | 2009-01-01 |
PublicationDate_xml | – month: 01 year: 2009 text: 2009-01-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Breast cancer research : BCR |
PublicationTitleAlternate | Breast Cancer Res |
PublicationYear | 2009 |
Publisher | BioMed Central Ltd National Library of Medicine - MEDLINE Abstracts BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: National Library of Medicine - MEDLINE Abstracts – name: BioMed Central |
References | 7585552 - Cancer Res. 1995 Nov 1;55(21):5063-8 12038707 - Breast Cancer Res Treat. 2002 Mar;72(2):163-72 8521507 - Cell. 1995 Dec 15;83(6):835-9 6852366 - Dev Biol. 1983 Jun;97(2):274-90 7557380 - Genes Dev. 1995 Sep 15;9(18):2266-78 10737785 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3044-9 8175886 - J Cell Biol. 1994 May;125(3):681-93 10732327 - J Soc Gynecol Investig. 2000 Jan-Feb;7(1 Suppl):S33-7 11897499 - J Steroid Biochem Mol Biol. 2002 Feb;80(2):137-48 12057913 - Am J Pathol. 2002 Jun;160(6):2081-93 7485387 - Am J Pathol. 1995 Nov;147(5):1228-37 7979245 - Annu Rev Biochem. 1994;63:451-86 12809600 - Cell. 2003 Jun 13;113(6):685-700 10428026 - Cell. 1999 Jul 23;98(2):137-46 12242106 - Biochim Biophys Acta. 2002 Oct 2;1603(1):1-9 9459191 - J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):251-9 11250717 - Breast Cancer Res. 2000;2(4):252-7 10935020 - J Mammary Gland Biol Neoplasia. 1997 Oct;2(4):323-34 18848450 - Trends Cell Biol. 2008 Nov;18(11):560-74 7891678 - Mol Cell Biol. 1995 Apr;15(4):1847-57 10662785 - J Cell Biol. 2000 Feb 7;148(3):615-24 17038622 - Science. 2006 Oct 13;314(5797):298-300 16049327 - Am J Pathol. 2005 Aug;167(2):409-17 12663498 - Carcinogenesis. 2003 Mar;24(3):403-9 11477119 - J Clin Pathol. 2001 Aug;54(8):624-30 14680479 - Breast Cancer Res. 2004;6(1):1-11 10527668 - Mol Genet Metab. 1999 Oct;68(2):182-90 12975354 - J Cell Biol. 2003 Sep 15;162(6):1123-33 9708806 - Am J Pathol. 1998 Aug;153(2):457-67 1512297 - J Cell Biol. 1992 Sep;118(5):1271-82 9435255 - Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):696-701 1794314 - Development. 1991 Jun;112(2):439-49 8573787 - Mol Biol Cell. 1995 Oct;6(10):1287-303 12486206 - Exp Biol Med (Maywood). 2002 Dec;227(11):969-80 PA Mote (2372_CR34) 2002; 72 WP Bocchinfuso (2372_CR28) 1997; 2 JE Fata (2372_CR10) 2004; 6 MD Sternlicht (2372_CR22) 1999; 98 BS Wiseman (2372_CR26) 2003; 162 WL Kraus (2372_CR12) 1995; 15 PA Mote (2372_CR33) 2001; 54 CM Nelson (2372_CR29) 2006; 314 YC Chou (2372_CR9) 2003; 24 Y Shi (2372_CR15) 2003; 113 G Shyamala (2372_CR7) 2000; 97 G Shyamala (2372_CR3) 1997; 63 JP Lydon (2372_CR4) 1995; 9 N Koshikawa (2372_CR23) 2000; 148 D Medina (2372_CR8) 2002; 1603 CJ Sympson (2372_CR20) 1994; 125 SA Leonhardt (2372_CR24) 2002; 227 RS Talhouk (2372_CR19) 1992; 118 MJ Duffy (2372_CR25) 2000; 2 JM Williams (2372_CR18) 1983; 97 JP Witty (2372_CR27) 1995; 6 G Shyamala (2372_CR6) 1998; 95 JD Graham (2372_CR32) 1995; 55 MJ Tsai (2372_CR2) 1994; 63 G Shyamala (2372_CR5) 1999; 68 BS Katzenellenbogen (2372_CR11) 2000; 7 DJ Mangelsdorf (2372_CR1) 1995; 83 RG Rowe (2372_CR31) 2008; 18 RS Talhouk (2372_CR13) 1991; 112 KB Ewan (2372_CR14) 2005; 167 G Shyamala (2372_CR30) 2002; 80 MH Barcellos-Hoff (2372_CR16) 1995; 147 KB Ewan (2372_CR17) 2002; 160 N Thomasset (2372_CR21) 1998; 153 |
References_xml | – volume: 83 start-page: 835 year: 1995 ident: 2372_CR1 publication-title: Cell doi: 10.1016/0092-8674(95)90199-X contributor: fullname: DJ Mangelsdorf – volume: 68 start-page: 182 year: 1999 ident: 2372_CR5 publication-title: Mol Genet Metab doi: 10.1006/mgme.1999.2897 contributor: fullname: G Shyamala – volume: 125 start-page: 681 year: 1994 ident: 2372_CR20 publication-title: J Cell Biol doi: 10.1083/jcb.125.3.681 contributor: fullname: CJ Sympson – volume: 162 start-page: 1123 year: 2003 ident: 2372_CR26 publication-title: J Cell Biol doi: 10.1083/jcb.200302090 contributor: fullname: BS Wiseman – volume: 112 start-page: 439 year: 1991 ident: 2372_CR13 publication-title: Development doi: 10.1242/dev.112.2.439 contributor: fullname: RS Talhouk – volume: 147 start-page: 1228 year: 1995 ident: 2372_CR16 publication-title: Am J Pathol contributor: fullname: MH Barcellos-Hoff – volume: 118 start-page: 1271 year: 1992 ident: 2372_CR19 publication-title: J Cell Biol doi: 10.1083/jcb.118.5.1271 contributor: fullname: RS Talhouk – volume: 7 start-page: S33 year: 2000 ident: 2372_CR11 publication-title: J Soc Gynecol Investig doi: 10.1016/S1071-5576(99)00058-1 contributor: fullname: BS Katzenellenbogen – volume: 63 start-page: 451 year: 1994 ident: 2372_CR2 publication-title: Annu Rev Biochem doi: 10.1146/annurev.bi.63.070194.002315 contributor: fullname: MJ Tsai – volume: 55 start-page: 5063 year: 1995 ident: 2372_CR32 publication-title: Cancer Res contributor: fullname: JD Graham – volume: 72 start-page: 163 year: 2002 ident: 2372_CR34 publication-title: Breast Cancer Res Treat doi: 10.1023/A:1014820500738 contributor: fullname: PA Mote – volume: 9 start-page: 2266 year: 1995 ident: 2372_CR4 publication-title: Genes Dev doi: 10.1101/gad.9.18.2266 contributor: fullname: JP Lydon – volume: 113 start-page: 685 year: 2003 ident: 2372_CR15 publication-title: Cell doi: 10.1016/S0092-8674(03)00432-X contributor: fullname: Y Shi – volume: 2 start-page: 252 year: 2000 ident: 2372_CR25 publication-title: Breast Cancer Res doi: 10.1186/bcr65 contributor: fullname: MJ Duffy – volume: 160 start-page: 2081 year: 2002 ident: 2372_CR17 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)61158-3 contributor: fullname: KB Ewan – volume: 227 start-page: 969 year: 2002 ident: 2372_CR24 publication-title: Exp Biol Med (Maywood) doi: 10.1177/153537020222701104 contributor: fullname: SA Leonhardt – volume: 148 start-page: 615 year: 2000 ident: 2372_CR23 publication-title: J Cell Biol doi: 10.1083/jcb.148.3.615 contributor: fullname: N Koshikawa – volume: 2 start-page: 323 year: 1997 ident: 2372_CR28 publication-title: J Mammary Gland Biol Neoplasia doi: 10.1023/A:1026339111278 contributor: fullname: WP Bocchinfuso – volume: 97 start-page: 274 year: 1983 ident: 2372_CR18 publication-title: Dev Biol doi: 10.1016/0012-1606(83)90086-6 contributor: fullname: JM Williams – volume: 1603 start-page: 1 year: 2002 ident: 2372_CR8 publication-title: Biochim Biophys Acta contributor: fullname: D Medina – volume: 167 start-page: 409 year: 2005 ident: 2372_CR14 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)62985-9 contributor: fullname: KB Ewan – volume: 18 start-page: 560 year: 2008 ident: 2372_CR31 publication-title: Trends in Cell Biology doi: 10.1016/j.tcb.2008.08.007 contributor: fullname: RG Rowe – volume: 314 start-page: 298 year: 2006 ident: 2372_CR29 publication-title: Science doi: 10.1126/science.1131000 contributor: fullname: CM Nelson – volume: 80 start-page: 137 year: 2002 ident: 2372_CR30 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/S0960-0760(01)00182-0 contributor: fullname: G Shyamala – volume: 95 start-page: 696 year: 1998 ident: 2372_CR6 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.2.696 contributor: fullname: G Shyamala – volume: 24 start-page: 403 year: 2003 ident: 2372_CR9 publication-title: Carcinogenesis doi: 10.1093/carcin/24.3.403 contributor: fullname: YC Chou – volume: 6 start-page: 1287 year: 1995 ident: 2372_CR27 publication-title: Mol Biol Cell doi: 10.1091/mbc.6.10.1287 contributor: fullname: JP Witty – volume: 63 start-page: 251 year: 1997 ident: 2372_CR3 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/S0960-0760(97)00128-3 contributor: fullname: G Shyamala – volume: 97 start-page: 3044 year: 2000 ident: 2372_CR7 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.97.7.3044 contributor: fullname: G Shyamala – volume: 54 start-page: 624 year: 2001 ident: 2372_CR33 publication-title: J Clin Pathol doi: 10.1136/jcp.54.8.624 contributor: fullname: PA Mote – volume: 6 start-page: 1 year: 2004 ident: 2372_CR10 publication-title: Breast Cancer Res doi: 10.1186/bcr634 contributor: fullname: JE Fata – volume: 153 start-page: 457 year: 1998 ident: 2372_CR21 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)65589-7 contributor: fullname: N Thomasset – volume: 98 start-page: 137 year: 1999 ident: 2372_CR22 publication-title: Cell doi: 10.1016/S0092-8674(00)81009-0 contributor: fullname: MD Sternlicht – volume: 15 start-page: 1847 year: 1995 ident: 2372_CR12 publication-title: Mol Cell Biol doi: 10.1128/MCB.15.4.1847 contributor: fullname: WL Kraus |
SSID | ssj0017858 |
Score | 2.0265913 |
Snippet | Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic... Abstract Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands... Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A... INTRODUCTIONExpression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A... INTRODUCTION: Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A... |
SourceID | pubmedcentral biomedcentral proquest gale crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | R72 |
SubjectTerms | Animals Breast cancer Development and progression Estradiol - pharmacology Estrogen Genetic aspects Hormone receptors Hyperplasia Mammary Glands, Animal - drug effects Mammary Glands, Animal - pathology Mice Mice, Transgenic Physiological aspects Progesterone Progesterone - pharmacology Receptors, Estrogen - physiology Receptors, Progesterone - genetics Receptors, Progesterone - physiology Research article Risk factors |
SummonAdditionalLinks | – databaseName: PubMed Central dbid: RPM link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbaHoZdhq3dw2u36TBsJzfxQw8fg6JFMSBDMaxAb4b1MBKgkYPELbDrfvlI2WmrAbvsGpKIZJESSX2kAD5bWxVZW7q0kVqnJTdtqgulU0WZfMHzRoXXGubfxeV1-e2G3-wB39XCBNC-0ctTf7s69ctFwFauV2ayw4lNruZnuazQU8gn-7CPCroL0cerA6nCo5y4A_CUl1k2VMqiHy0m2myoo1doFEooOqo2isrcb6PT6e89-skhFQMon5xIFy_hxehKstkw5Few5_whHM08htGrX-wLC-DOkDU_hGfz8Q79CH6fb_tNh3rDGm8Z4bNCs4TOO4a7n1vT8zts0dw7Zsn-vekZQRC3bOkZeosMuZuQuqK8Iuva8OMCw9nNGj1xHAsj2FhHuV0SufqRzlhPJyL-JRJXuDO9huuL859nl-n4EkOqRSH6FN0qU9g2q5RwrUYX0FRWNwV-_FaKkiuhleZWllPjrJRZ0xpjZd7k3BmLPlBWvIEDj_N4B2zaZtqhAmRGK-JXhctLYx1XrlIYnCVQRCtSr4euGzX1wY4paJL1uKQJsN26PQiE8EaJR5avtJ41GS6Km2asP8BhUQusekbBL4aL1TSBk4gTDc5E5OOdRtSjwW9r6mGDsbYqEvj0QCVBwrB5190hC1W5VQJnyP7BIam5HpUmJ_B2ULDHyYwKm4CMVC_6PDEFrSe0Cx-t5f1_Sx7D8-EOjRJPJ3DQb-7cB3TFev0xmN4fMXA5Xg priority: 500 providerName: National Library of Medicine |
Title | Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19788752 https://www.proquest.com/docview/236125483 https://search.proquest.com/docview/21468964 https://search.proquest.com/docview/734192789 http://dx.doi.org/10.1186/bcr2408 https://pubmed.ncbi.nlm.nih.gov/PMC2790852 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1da9RAcKgVxJeirdrYeq4g-rR4yWY_8ngtLUWoiFgovoTsR7iCJsddWuirv9yZTXq9FH3xNTNDdnd2dmdm5wPgvfeFSOs88Epby3Ppam6FsdyQJ1_JrDKxW8P5F3V2kX--lJdb8O7vL_ipUZ-sW1IZrkfwOKNKKmSQH_1YPxRoE1tworxLLvM07fNiNwkfZLL_HF1AD4_hjXtoHCO5cemcPoOdQVtks569z2ErNLuwN2vQUv51yz6wGL8ZHeO78OR8eCbfg98nq27Z4tZgVeMZhWDFeghtExgecGFBHXbYvLoJzJOIN65jFGW4YlcNQ4WQIXYVvVPkOmRtHT_O0WJdLlDZxrEwigxryX1LJF-_8Rnr6NLDXyKQOty_gIvTk-_HZ3xotsCtEqrjqDk54eu0MCrUFrU8V3hbCTwAaq1yaZQ1VnqdT13wWqdV7ZzXWZXJ4DyqOal4CdsNzmMf2LRObUAep84awjciZLnzQZpQGLS_EhAjjpSLvrBGSaWuxxCUunLgYwLsjm9rgmjBGHWP8pH4WZJsIrmrhhQDHBZVuSpnZN-iRVhMEzgcYaJMuRH44G5HlINMr0oqU4PmtBEJvF1DiZDC1JrQXiMKJbIVCmfI_oGhqX4eZR8n8KrfYPeTKSiyU2YJ6NHWGy3PGNJczWNF8EwXqDpnr_9rYQ_gaf9ERn6lQ9jultfhDWpanZ1ED8UkStwkOsL-AN1AMKc |
link.rule.ids | 108,230,315,730,783,787,867,888,24949,27936,27937,53804,53806,76140,76141 |
linkProvider | BioMedCentral |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtRAzCpFgl4QtDxCWzoHBKfA5jGPHBfUskC3QlUrVVyizCPaSm2yyqaVuPLl2JPsdlOJS69rWzuTsT22xw-A99ZmSVSmLiyk1mHKTRnqROlQUSRf8LhQflrD9ERMztMfF_xiA74ta2F0042swR03fbub2af1SvQrr76XWWOd0CvxWZuGmnU9gsfol6ckoadffq-eE6TygzpRK_CQp1HUVc-uE96rd78aXFP3lfXabTXMpFy7mo6ew7PepmTjbrUvYMNV27AzrtCfvv7DPjCf5enD59vwZNo_pu_A38NF29TIQKyoLKNELd81oa4cQzXo5jSHh82KW8csKYLKtIxyERfssmJoNjLELnwMiwKMrC79jzP0a5s5muS4Fkb5YzUFeYnk12k4Zi1djfiXCLxGFfUSzo8Oz75Own4kQ6hFItoQ7SuT2DLKlHClRlvQZFYXCaqJUoqUK6GV5lamI-OslFFRGmNlXMTcGYvGUJS8gs0K9_EG2KiMtENOiIxWhK8SF6fGOq5cptBLCyAZnEg-79pv5NQQewhBjsj7cwyALc9tReD9HCXuUD7SeeYkwUhuir4QAZdFvbDyMXnB6DdmowD2BpgoeWYA3l1yRN5L_iKnZjbodKskgIMVlAgpma1y9Q2iULlbJnCH7D8YkrrsUY1yAK87BrvbTEb5nzwOQA5Yb_B5hpDqcub7hscyQwM7fvugD3sATydn0-P8-PvJz13Y6h7VKBK1B5ttc-P20TZr9Tsvd_8AsChBFA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtRAzCpFqrggaIGmLXQOCE6hm8c8clygq-XRqqqoVHGJMo9oK9pklU0rceXLsSfZ7aYSF25R7FEyM7bH9vgB8NbaLInK1IWF1DpMuSlDnSgdKvLkCx4XyndrODkV04v06yW_3IDpMhdGN13LGpxx05e7mX1Yz0S_9uIbH8yvo7ktO65X4kibhqp1PYLHaJin1MTh_OPP1X2CVL5TJ4oFHvI0irr02fWBDxLerwfn1ENpvXZcDUMp186myTN42iuVbNxRwXPYcNU27IwrNKhvfrN3zId5ev_5Nmyd9LfpO_DneNE2NVIQKyrLKFLLl02oK8dQDro5NeJhs-LOMUuSoDIto2DEBbuqGOqNDLEL78QiDyOrS_9yhoZtM0edHP-FUQBZTV5eGnJ2Ho5ZS2cjfhKBNyijXsDF5PjHp2nY92QItUhEG6KCZRJbRpkSrtSoDJrM6iJBOVFKkXIltNLcynRknJUyKkpjrIyLmDtjURuKkpewWeE8doGNykg7JIXIaEX4KnFxaqzjymUKzbQAksGO5POu_kZOFbGHECSJvN_HANhy31YDvKGjxD3Ke9rPnFiYCKnoMxHwt6gYVj4mMxgNx2wUwMEAE1nPDMD7S4rIe9Zf5FTNBq1ulQRwuILSQIpmq1x9iyiU75YJnCH7B4akMnuUpBzAq47A7ieTUQAojwOQA9IbLM8QUl3NfOHwWGaoYcd7_7Wwh7B19nmSf_9y-m0fnnSXauSJOoDNtrl1r1E3a_Ubz3Z_AReYQN8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estrogen+and+progesterone+receptors+have+distinct+roles+in+the+establishment+of+the+hyperplastic+phenotype+in+PR-A+transgenic+mice&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Simian%2C+Marina&rft.au=Bissell%2C+Mina&rft.au=Barcellos-Hoff%2C+Mary&rft.au=Shyamala%2C+Gopalan&rft.date=2009-01-01&rft.pub=BioMed+Central+Ltd&rft.issn=1465-5411&rft.eissn=1465-542X&rft.volume=11&rft.issue=5&rft.spage=R72&rft.epage=R72&rft_id=info:doi/10.1186%2Fbcr2408&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_bcr2408 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |